Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
This module explores unique professional issues that accompany advanced oncology nursing practice. Explore topics including APRN education, accreditation, licensure, and certification standards, as well as professional roles and state practice acts.
Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.
Human epidermal growth factor receptor 2 proteins are involved in normal cellular growth and are found on the surface of all breast cells. Approximately 20% of breast cancers are HER2 positive, meaning they have high levels of HER2 protein, and those cancers typically grow and metastasize more quickly than other types of breast cancer.